SAB Biotherapeutics, Inc. (SABSW)Miami Beach, United States | NasdaqCM
0.03 USD
+0.00
(1.575%)
⇧
(Aug. 28, 2026, 1 p.m.
EDT)
|
Hot Take ↕ | Aug. 22, 2026, 1:30 a.m. EDT
The security is currently trapped in a severe structural decline, having lost nearly all its value over the trailing period while generating massive negative free cash flow and posting deep losses on both assets and equity. Despite a technically tight trading band and recent intraday spikes, the underlying business fundamentals are deteriorating rapidly with no path to profitability visible, making it a clear avoid for long-term capital preservation. There is no dividend to provide any income cushion, and the lack of historical price data prevents any assessment of long-term resilience, leaving the investment case entirely dependent on speculative biotech catalysts rather than financial performance. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 2.389 |
| Trailing P/E | 0.09 |
| Beta | 0.53 |
| Website | https://www.sab.bio |
| Attribute | Value |
|---|---|
| Address1 | 777 W 41st St. |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 0.531 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 2.572 |
| City | Miami Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0258 |
| Current Ratio | 9.221 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0258 |
| Day Low | 0.0258 |
| Debt To Equity | 2.389 |
| Display Name | SAB Biotherapeutics |
| Ebitda | -68,707,776 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | 0.292 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0258 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.0258 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.0258 - 0.0258 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 62,043,604 |
| Free Cashflow | -28,842,384 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 86 |
| Fullday Change | 0.00040000118 |
| Fullday Change Percent | 1.5748078 |
| Fullday Price | 0.0258 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -48,268,332 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. |
| Long Name | SAB Biotherapeutics, Inc. |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_268941400 |
| Net Income To Common | -21,787,718 |
| Open | 0.0477 |
| Operating Cashflow | -53,937,112 |
| Operating Margins | 0.0 |
| Phone | 305 845 2813 |
| Previous Close | 0.0254 |
| Price Hint | 4 |
| Price To Book | 0.010031104 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.926 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00040000118 |
| Regular Market Change Percent | 1.5748078 |
| Regular Market Day High | 0.0258 |
| Regular Market Day Low | 0.0258 |
| Regular Market Day Range | 0.0258 - 0.0258 |
| Regular Market Open | 0.0477 |
| Regular Market Previous Close | 0.0254 |
| Regular Market Price | 0.0258 |
| Regular Market Time | 1,787,936,407 |
| Regular Market Volume | 9,941 |
| Return On Assets | -0.33458 |
| Return On Equity | -0.11266 |
| Sand P52 Week Change | 0.20204377 |
| Sector | |
| Sector Key | |
| Source Interval | 15 |
| State | FL |
| Symbol | SABSW |
| Total Cash | 102,632,000 |
| Total Cash Per Share | 1.128 |
| Total Debt | 5,132,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.292 |
| Trailing P E | 0.08835617 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 9,941 |
| Website | https://www.sab.bio |
| Zip | 33,140 |